IO360° Summit - Immuno-Oncology 360 Conference, New-York, New York Marriott, US| February 27-29, 2024
Dr. Tehila Ben Moshe, Our CEO is presenting at the IO360° Summit - Immuno-Oncology 360 Conference.
Tehila will be giving two talks on BND-35, our anti ILT3/LILRB4 antibody and on our INspire platform technology for intracellular delivery of antibodies.
First presentation titled: “INspire - A novel intracellular delivery platform for biologics – expanding the boundaries of biologics.” TRACK A: DISCOVERY, PRECLINICAL & PAYLOAD MODIFICATION (SALON E), Payload Delivery & Modification Lightning Talks
Tuesday, February 27, 2024
04:10 PM - 04:30 PM
Second presentation titled: “BND-35, a superior anti-ILT3 antibody that modulates the suppressive tumor microenvironment.” IO360° BIOTECH SHOWCASE B (NORTHSIDE BALLROOM)
Wednesday, February 28, 2024
10:20 AM - 10:50 AM
19th Annual Meeting of The Medicinal Chemistry Section of the Chemical Society Biomed Israel, Weizmann Institute of Science, Rehovot, Israel | July 20th, 2023
Dr. Lilach Chen our Technology Development Manager, presented at the 19th Annual Meeting of The Medicinal Chemistry Section of the Israel Chemical Society at the Weizmann Institute of Science. She discussed the practical application of INspire, our intracellular delivery platform for delivering antibody-based agents into cancer cells, demonstrating a substantial reduction in solid tumors size, in mouse models.
Lilach discussed the delivery of our proprietary intracellular nanobodies, for targeting mutated and WT KRAS.
Biomed Israel, Tel-Aviv, David Intercontinental, Israel | May 16-18, 2023
Ilana Mandel, Our VP R&D presented at the Biomed 2023 conference, the title of her talk was: "INspire – expanding the boundaries of biologics – intracellular delivery of biological agents”.
The talk was part of the session “Are Cancer Therapeutics Fulfilling the Promise?” that was moderated by Tehila Ben-Moshe and Yaron Daniely that also hosted Giovanni Abbadessa (Sanofi) and Ru Walker (Regeneron) at BIOMED 2023.
Targeted Intracellular Delivery Summit March 8 – 9, 2023 | Boston, Hilton Boston Back Bay, USA.
A truly inspiring presentation of INspire - Bionds' intracellular delivery platform for biologics, given by Avidor Shulman our CTO.
Avidor presented at the "Targeted Intracellular Delivery Summit" held in Boston.
INspire is expanding the boundaries of biologics, by enabling for the first time ever, delivery of biological agents, such as nanobodies, antibodies and proteins into cells, focusing on intracellular, undruggable targets.
J.P. Morgan 41st Annual Healthcare Conference (JPM 2023) January 9 – 12, 2023 | San Francisco, CA, USA.
Dr. Tehila Ben Moshe our CEO and Ori Shilo our CFO participated in the J.P. Morgan 41st Annual Healthcare Conference that took place in San Francisco.
ASCO Annual Meeting | June 3-7, 2022
Biond Biologics presented together with Sanofi at The ASCO 2022 Annual Meeting pre-clinical translational Data of SAR444881 (BND-22) at the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting that took place in Chicago, Illinois, June 3-7, 2022.
The poster presented pre-clinical translational data including potential patient enrichment biomarkers for SAR444881 (BND-22) a first-in-class anti-ILT2 monoclonal antibody for cancer immunotherapy.
AACR Annual Meeting | April 8-13, 2022
Biond Biologics gave an oral presentation for BND-67, an Inhibitor of CD28 shedding, a potential novel resistance mechanism to anti PD-1 therapies, at the American Association for Cancer Research (AACR) 2022 in New Orleans, Louisiana.
Biond gave the oral presentation in the session of: “Experimental and Molecular Therapeutics - Elucidating Disease Biology and Drug Resistance Mechanisms”. The presentation title was: “CD28 shedding is a novel resistance mechanism to anti PD-1 therapy”, (Abstract #654)
BIO Europe Spring | March 28-31, 2022
We participated in the BIO Europe Spring that was held March 28-31, 2022 ad presented our immune-Oncology pipeline and our platform technology for intracellular delivery of biologics.
2nd Immuno-Oncological Meeting of the Israel Immunological Society (2022) February 22-24, 2022| Haifa, Israel
Biond Biologics presented a poster at the Israel Immunological Meeting that took place in Haifa, Israel, February 22-24, 2022.
The poster title was “CD28 shedding is a novel immune-regulatory mechanism associated with anti-PD-1 resistance”.
Biond reported the discovery of a novel regulatory mechanism which blocks the CD28/B7 activation pathway and presented data about the development of therapeutic drug candidate for the inhibition of this regulatory mechanism (BND-67).
J.P. Morgan 38th Annual Healthcare Conference (JPM 2020) January 13 – 16, 2020 | San Francisco, CA, USA.
Dr. Tehila Ben Moshe our CEO and Ori Shilo our CFO participated in the J.P. Morgan 38th Annual Healthcare Conference that took place in San Francisco and shared the latest update on Biond’s pipeline.
18th National Life Sciences & Technology Week May 14 – 16, 2019 | David InterContinental Tel Aviv, Israel.
Biond’s team led by Dr. Tehila Ben Moshe our CEO, attended the Jefferies 2019 London Healthcare Conference and presented an update on the company progress in the field of Immuno-Oncology developing biological agents that are aimed at overcoming immune evasion mechanism activated by tumors.
18th National Life Sciences & Technology Week May 14 – 16, 2019 / David InterContinental Tel Aviv, Israel.
We were proud to be part for the 2nd year, of the MIXiii-BIOMED conference, together with many of the companies that compose the biotech and pharma ecosystem in Israel.
17th National Life Sciences & Technology Week, May 15 – 17, 2018 } David InterContinental Tel Aviv, Israel.
It was a great pleasure to meet key opinion leaders and lead stakeholders of the biotech and pharma ecosystem in Israel in the MIXiii-BIOMED 2018 conference.
© Copyright 2020. Designed by YuvalDesign